|Trials, Year (Ref. #)||Population||Intervention||Duration of Follow-Up, yrs||Events||RR (95% CI)||Achieved Power⁎|
|DART, 1989 (222)||2,033 men with recent (average ∼1 month prior) MI||Advice to consume fatty fish 2 servings/week vs. usual care||2|
|GISSI-Prevenzione Trial, 1999 (169)||11,324 men with recent (≤3 months prior) MI||882 mg/day EPA+DHA vs. usual care||3.5|
|DART 2, 2003 (221)||3,114 men with angina||Advice to consume fatty fish 2 servings/week vs. usual care||3–9|
|JELIS, 2007 (220)||18,645 men and women with total cholesterol ≥6.5 mmol/l||1.8 g/day EPA vs. usual care||5|
|GISSI-Heart Failure 2008 (223)||6,975 patients with chronic congestive heart failure||882 mg/day EPA+DHA vs. placebo||3.9|
|Alpha-Omega, 2010 (17)||4,837 patients with a history of past (average ∼4.3 yrs prior) MI||376 mg/day EPA+DHA vs. a combined control group receiving either placebo or ALA 1.9 g/day||3.3|
|Omega, 2010 (219)||3,851 patients with recent (≤2 weeks prior) MI||840 mg/day EPA+DHA vs. placebo||1|
|SU.FOL.OM3, 2010 (224)||2,501 patients with a history of past (average ∼100 days prior) acute coronary or cerebral ischemic event||600 mg/day EPA+DHA vs. a combined control group receiving either placebo or B vitamins (5-methyltetrahydrofolate, 560 μg; B-6, 3 mg; and B-12, 20 μg)||4.2||1.08 (0.79–1.47) Not reported|
CHD = coronary heart disease; CI = confidence interval; DART = Diet and Reinfarction Trial; IHD = ischemic heart disease; JELIS = Japan EPA Lipid Intervention Study; MI = myocardial infarction; RCT = randomized controlled trial; SU.FOL.OM3 = Supplementation en Folates et Omega-3; other abbreviations as in Table 1.
↵⁎ On the basis of the actual number of events, 2-sided alpha = 0.05, and a relative risk (RR) reduction of 25% for n-3 fatty acid treatment.